Drug Type Small molecule drug |
Synonyms BKU, Urapidil (JP17/INN), Urapidil Hydrochloride + [13] |
Target |
Action antagonists |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (20 Sep 1988), |
Regulation- |
Molecular FormulaC20H29N5O3 |
InChIKeyICMGLRUYEQNHPF-UHFFFAOYSA-N |
CAS Registry34661-75-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysuria | Japan | 11 Nov 1999 | |
Urination Disorders | Japan | 30 Jun 1995 | |
Hypertension | Japan | 20 Sep 1988 |
Not Applicable | 30 | Urapidil treatment group | wrvnpfabws(ytrhhnxjhu) = isccqsejri iaccyabrkw (aeqgohaftz ) View more | - | 26 May 2018 | ||
Nitroglycerin treatment group | wrvnpfabws(ytrhhnxjhu) = nbnupuvcgd iaccyabrkw (aeqgohaftz ) View more | ||||||
Not Applicable | Calculus, Ureteral Adjuvant | 80 | pqgoluqqyl(rrliccpctj) = pqwglzkiso iihpfwwetl (rwtntfoovp ) View more | Positive | 01 Apr 2012 | ||
Placebo | pqgoluqqyl(rrliccpctj) = zihldffqro iihpfwwetl (rwtntfoovp ) View more |